Evidence map›Paper›PMID 26106161›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Less than the sum of its parts, a leinamycin precursor has superior properties.

William P Katt, Richard A Cerione

Abstract readComment
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

William P KattDepartment of Molecular Medicine, Veterinary Medical Center, Cornell University, Ithaca, NY 14853;
Richard A CerioneDepartment of Molecular Medicine, Veterinary Medical Center, Cornell University, Ithaca, NY 14853; Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY 14853 rac1@cornell.edu.

Funding

Overall (pp. 40-62)P41GM103485 · NIGMS · CORNELL UNIVERSITY · PI CERIONE, RICHARD A. · 2012 to 2018
$15.5M
RECONSTITUTION OF GROWTH FACTOR RECEPTOR/TYROSINE KINASER01GM040654 · NIGMS · CORNELL UNIVERSITY ITHACA · PI CERIONE, RICHARD A. · 1988 to 2016
$5.6M
NIGMS NIH HHS P41 GM103485NIGMS NIH HHS R01 GM040654
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsHumansLactamsMacrolidesMaleProdrugsReactive Oxygen SpeciesThiazolesThionesAntineoplastic AgentsLactamsMacrolidesProdrugsReactive Oxygen SpeciesThiazolesThiones

Identifiers

PMID26106161
PMCPMC4500279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.